Compare Stocks: KRTX, TEVA, ONC, and RPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRTX Karuna Therapeutics	$329.83	$327.01	$158.38 ▼ $329.99	$12.58B	1.18	832,048 shs	N/A
ONC BeOne Medicines	$366.73 -1.5%	$325.53	$253.95 ▼ $385.22	$40.89B	0.49	401,641 shs	341,579 shs
RPRX Royalty Pharma	$60.85 -1.7%	$58.16	$34.08 ▼ $62.46	$35.60B	0.43	2.71 million shs	1.70 million shs
TEVA Teva Pharmaceutical Industries	$36.45 -3.1%	$34.31	$17.94 ▼ $38.37	$43.84B	0.86	5.16 million shs	3.14 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRTX Karuna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ONC BeOne Medicines	-1.55%	-2.07%	+12.08%	+27.37%	+22.19%
RPRX Royalty Pharma	-1.73%	-0.75%	+2.82%	+9.13%	+68.75%
TEVA Teva Pharmaceutical Industries	-3.30%	-2.46%	+5.50%	+3.19%	+101.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRTX Karuna Therapeutics	$329.83	$327.01	$158.38 ▼ $329.99	$12.58B	1.18	832,048 shs	N/A
ONC BeOne Medicines	$366.73 -1.5%	$325.53	$253.95 ▼ $385.22	$40.89B	0.49	401,641 shs	341,579 shs
RPRX Royalty Pharma	$60.85 -1.7%	$58.16	$34.08 ▼ $62.46	$35.60B	0.43	2.71 million shs	1.70 million shs
TEVA Teva Pharmaceutical Industries	$36.45 -3.1%	$34.31	$17.94 ▼ $38.37	$43.84B	0.86	5.16 million shs	3.14 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRTX Karuna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ONC BeOne Medicines	-1.55%	-2.07%	+12.08%	+27.37%	+22.19%
RPRX Royalty Pharma	-1.73%	-0.75%	+2.82%	+9.13%	+68.75%
TEVA Teva Pharmaceutical Industries	-3.30%	-2.46%	+5.50%	+3.19%	+101.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRTX Karuna Therapeutics	0.00	N/A	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$402.14	9.66% Upside
RPRX Royalty Pharma	3.00	Buy	$60.86	0.01% Upside
TEVA Teva Pharmaceutical Industries	2.90	Moderate Buy	$42.22	15.84% Upside

Current Analyst Ratings Breakdown

Latest KRTX, TEVA, ONC, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/12/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
8/12/2026	TEVA Teva Pharmaceutical Industries	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $42.00
8/10/2026	ONC BeOne Medicines	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$370.00
8/7/2026	ONC BeOne Medicines	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	RPRX Royalty Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$58.00 ➝ $62.00
8/6/2026	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/6/2026	RPRX Royalty Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$66.00
8/6/2026	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$65.00
8/6/2026	ONC BeOne Medicines	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	ONC BeOne Medicines	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$403.00 ➝ $407.00

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRTX Karuna Therapeutics	$654K	19,239.07	N/A	N/A	$33.24 per share	9.92
ONC BeOne Medicines	$5.34B	7.54	$3.85 per share	95.30	$47.13 per share	7.78
RPRX Royalty Pharma	$2.38B	14.71	$4.70 per share	12.96	$17.02 per share	3.58
TEVA Teva Pharmaceutical Industries	$17.26B	2.46	$3.61 per share	10.09	$6.66 per share	5.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRTX Karuna Therapeutics	-$433.68M	-$11.72	N/A	N/A	N/A	N/A	-31.63%	-30.38%	N/A
ONC BeOne Medicines	$286.93M	$5.68	64.57	26.91	N/A	10.70%	14.23%	7.82%	N/A
RPRX Royalty Pharma	$770.95M	$1.45	41.97	11.00	1.44	32.14%	30.01%	14.91%	11/4/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	60.75	12.03	4.03	4.08%	32.64%	6.34%	11/4/2026 (Estimated)

Latest KRTX, TEVA, ONC, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion
8/5/2026	Q2 2026	RPRX Royalty Pharma	$1.27	$1.32	+$0.05	$0.04	$758.93 million	$674.14 million
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRTX Karuna Therapeutics	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.54%	+24.01%	64.83%	5 Years
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest KRTX, TEVA, ONC, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.6%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRTX Karuna Therapeutics	N/A	19.31	19.31
ONC BeOne Medicines	0.17	3.40	3.06
RPRX Royalty Pharma	0.88	2.80	2.80
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRTX Karuna Therapeutics	N/A
ONC BeOne Medicines	48.55%
RPRX Royalty Pharma	54.35%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
KRTX Karuna Therapeutics	13.20%
ONC BeOne Medicines	6.19%
RPRX Royalty Pharma	18.84%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRTX Karuna Therapeutics	339	38.15 million	33.16 million	Optionable
ONC BeOne Medicines	12,000	109.79 million	102.99 million	N/A
RPRX Royalty Pharma	80	575.00 million	466.67 million	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

KRTX, TEVA, ONC, and RPRX Headlines

Recent News About These Companies

Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

August 28 at 3:01 PM | pharmexec.comP

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

August 28 at 6:17 AM | globenewswire.com

Are Wall Street Analysts Predicting Deckers Outdoor Stock Will Climb or Sink?

August 28 at 4:59 AM | barchart.com

Health Brief: Pharma’s legal plan B

August 27 at 6:58 PM | washingtonpost.com

Turkey to probe alleged Teva antitrust violations

August 26 at 9:24 AM | en.globes.co.ilE

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

August 25, 2026 | finance.yahoo.com

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

August 25, 2026 | zacks.com

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High - Time to Buy?

August 25, 2026 | marketbeat.com

Teva share price hits 10-year high

August 23, 2026 | en.globes.co.ilE

X Square Capital LLC Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

August 23, 2026 | marketbeat.com

TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

August 20, 2026 | finance.yahoo.com

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

August 20, 2026 | finance.yahoo.com

TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

August 20, 2026 | zacks.com

AUPH Stock Rallies 6% After-Hours — Here’s Why

August 19, 2026 | stocktwits.comS

Aurinia Settles Patent Litigation with Teva

August 19, 2026 | businesswire.com

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 12-Month High - What's Next?

August 19, 2026 | marketbeat.com

FDA accepts Teva's NDA for ecopipam, grants priority review for pediatric Tourette syndrome

August 19, 2026 | thepharmaletter.comT

Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?

August 19, 2026 | finance.yahoo.com

Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?

August 19, 2026 | zacks.com

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

August 19, 2026 | globenewswire.com

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

August 17, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KRTX, TEVA, ONC, and RPRX Company Descriptions

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

BeOne Medicines NASDAQ:ONC

$366.73 -5.76 (-1.55%)

As of 08/28/2026 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Royalty Pharma NASDAQ:RPRX

$60.85 -1.07 (-1.73%)

As of 08/28/2026 04:00 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$36.45 -1.17 (-3.11%)

As of 08/28/2026 03:58 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRTX, TEVA, ONC, and RPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRTX, TEVA, ONC, and RPRX Earnings

Compare Dividends

Latest KRTX, TEVA, ONC, and RPRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRTX, TEVA, ONC, and RPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KRTX, TEVA, ONC, and RPRX Company Descriptions

Karuna Therapeutics NASDAQ:KRTX

BeOne Medicines NASDAQ:ONC

Royalty Pharma NASDAQ:RPRX

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools